Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

Obesity Clinical Trial

Official title:

Efficacy and Safety of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04487743
• Other study ID #: 202006108
• Secondary ID: HDSJ19LLLT
• Status: Recruiting
• Phase: Phase 3
• Start date: May 9, 2020
• Est. completion date: June 2022

Study information

• Verified date: July 2020
• Source: Xiangya Hospital of Central South University
• Contact: Jing Wu
• Phone: +86-13574120508
• Email: wujing0731[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either liraglutide or placebo. The primary outcome is to investigate the safety, tolerability from baseline to end of treatment.

Description:

We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 individuals (18-75 years of age, body-mass index ≥30 kg/m2 or BMI 27-30kg/m2 accompanied by at least one weight-related complication (treated or untreated hypertension, dyslipidemia, pre-diabetes)) were randomly assigned. All the patients provided written informed consent before participation. Key exclusion criteria were type 1 or 2 diabetes, the use of medications that cause clinically significant weight gain or loss, previous bariatric surgery, a history of pancreatitis, a history of major depressive or other severe psychiatric disorders, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either liraglutide or placebo using a computer-generated, centrally administered procedure. Patients, investigators, and the sponsor were unaware of the study-group assignments. The primary endpoint was change in bodyweight during the 28 weeks of the study in the intention-to-treat population. The proportion of people losing more than 5% of baseline weight was also assessed. Secondary efficacy endpoints included the proportion of people losing more than 10% of baseline weight was also assessed, change in waist circumference, hip circumference, WHR, systolic and diastolic blood pressure, fasting lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), glucose metabolism parameters (fasting plasma glucose, 2-hour post-challenge plasma glucose and glycosylated haemoglobin [HbA1c]).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Informed consent obtained before any trial-related activity takes place

• Obesity (BMI =30.0 kg/m2); or overweight (BMI =27.0 kg/m2) with treated or untreated co-morbid dyslipidemia (Low-density lipoprotein =3.38mmol/l (130 mg/dl), or triglycerides =1.7mmol/l (150 mg/dl), or high-density lipoprotein <1.04mmol/l (40 mg/dl) for males and <1.30mmol/l (50 mg/dl) for females) and/or hypertension (Systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg)

• Age =18 years, =75 years

Exclusion Criteria:

• Diagnosis of type 1 or type 2 diabetes per the judgment of the investigator

• HbA1c =6.5% or fasting plasma glucose =7.0 mmol/l or 2-hour post-challenge plasma glucose =11.1 mmol/liter (at screening)

• less than 5 kg self-reported change during the previous 3 months

• Previous treatment with GLP-1 receptor agonists (including liraglutide or exenatide) within the last 3 months

• Known or suspected hypersensitivity to trial product, related products or other GLP-1 receptor agonist

• Diet attempts using herbal supplements or over-the-counter medications within 1 months before screening, or use prescription drugs for weight loss within 3 months before screening (for example: orlistat, fenfluramine, maindole ) Or lipid dissolving injection (for example: lipolysis needle) treatment

• Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (more than 1 week),tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptiline, mirtazapin, paroxetine, phenelzine, clorpromazine, thioridazine, clozapine, lanzapine, valproic acid and its derivatives, and lithium)

• A history of malignant tumors within 5 years before screening (except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical operation)

• A history of severe heart disease is defined as: decompensated heart insufficiency (NYHA III-IV), and/or a history of unstable angina within 6 months before screening, and a history of myocardial infarction within 12 months

• Obesity induced by other endocrinologic disorders (e.g. Cushing's Syndrome)

• Suffer from gastrointestinal motility disorders or obstruction diseases, such as gastroparesis, gastroesophageal reflux disease

• Any lifetime history of a suicidal attempt or A history of any suicidal behavior in the last month prior to randomization

• A patient health questionnaire (PHQ-9) score of =15

• Montreal Cognitive Assessment Scale (MoCA) score <26 at screening;

• Any suicidal ideation of type 4 or 5 on the Columbian Suicidality Severity Rating Scale (C-SSRS) in the last month prior to randomization

• Untreated or uncontrolled hypothyroidism/hyperthyroidism defined as thyroid-stimulating hormone >6 mIU/liter or <0.4 mIU/liter

• Screening calcitonin =50 ng/liter

• Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC) or Personal history of non-familial medullary thyroid carcinoma

• History of chronic pancreatitis or idiopathic acute pancreatitis or amylase = 3 times the upper limit of normal value during screening

• ALT or AST or TBiL>3 times the upper limit of normal value during screening

• Impaired renal function, defined as serum creatinine level =1.5mg/dL (132µmol/L) in men or =1.4mg/dL (123µmol/L) in women at screening

• Untreated or uncontrolled severe dyslipidemia, defined as blood LDL-C=190mg/dl (4.94mmol/L) and/or TG=500mg/dl (5.65mmol/L) at screening

• Uncontrolled treated/untreated hypertension (systolic blood pressure =160 mm Hg and/or diastolic blood pressure =100 mm Hg)

• Previous surgical treatment for obesity (excluding liposuction if performed >1 year before trial entry)

• According to the investigator's judgment, those who have a surgical plan during the trial period (except for minor operations)

• Participated in any weight loss clinical trials within 3 months before screening, and took any experimental drugs within 1 month (Re-screening is allowed once within the limit of the recruitment period)

• Known or suspected abuse of alcohol or narcotics within 6 months

• Poor compliance with restrictions on diet and behavior during screening

• Females of child-bearing potential who are pregnant, breast-feeding

• Participants intend to become pregnant or are not using adequate contraceptive methods or subjects who use hormonal contraceptives

• The investigator considers that it is not suitable for participants (for example, the investigator judges that severe obstructive sleep apnea will cause gastroesophageal reflux).

Related Conditions & MeSH terms

• Body Weight
• Obesity
• Overweight

Intervention

Drug:
• Liraglutide
Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
• placebo
Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification

Locations

Country	Name	City	State
China	Xiangya Hospital of Central South University	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline in Fasting Body Weight	mean change from baseline in fasting body weight (%) after 28-weeks of treatment.	Week 0, Week 28
Primary	Percentage of Subjects Losing at Least 5% of Baseline Fasting Body Weight.	Percentage of subjects losing at least 5% of baseline fasting body weight after 28-weeks of treatment.	Week 28
Secondary	Percentage of Subjects Losing More Than 10% of Baseline Fasting Body Weight.	Percentage of subjects losing >10% of baseline fasting body weight after 28-weeks of treatment	Week 28
Secondary	Mean Change From Baseline in Waist Circumference (cm)	mean change from baseline in waist circumference (cm) after 28-weeks of treatment	Week 0, Week 28